143 related articles for article (PubMed ID: 12869491)
1. Molecular monitoring in chronic myeloid leukemia patients who achieve complete cytogenetic remission on imatinib.
Lin F; Drummond M; O'Brien S; Cervantes F; Goldman J; Kaeda J
Blood; 2003 Aug; 102(3):1143. PubMed ID: 12869491
[No Abstract] [Full Text] [Related]
2. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses.
Kantarjian HM; Cortes JE; O'Brien S; Giles F; Garcia-Manero G; Faderl S; Thomas D; Jeha S; Rios MB; Letvak L; Bochinski K; Arlinghaus R; Talpaz M
Blood; 2003 Jan; 101(1):97-100. PubMed ID: 12393600
[TBL] [Abstract][Full Text] [Related]
3. BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML.
Press RD; Love Z; Tronnes AA; Yang R; Tran T; Mongoue-Tchokote S; Mori M; Mauro MJ; Deininger MW; Druker BJ
Blood; 2006 Jun; 107(11):4250-6. PubMed ID: 16467199
[TBL] [Abstract][Full Text] [Related]
4. Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy for posttransplantation chronic myelogenous leukemia relapse.
Kim YJ; Kim DW; Lee S; Min CK; Goh HG; Kim SH; Lee JY; Kim YL; Kim HJ; Kim HJ; Lee JW; Kim TG; Min WS; Kim CC
Biol Blood Marrow Transplant; 2004 Oct; 10(10):718-25. PubMed ID: 15389438
[TBL] [Abstract][Full Text] [Related]
5. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
[TBL] [Abstract][Full Text] [Related]
6. Monitoring minimal residual disease in BCR-ABL-positive chronic myeloid leukemia in the imatinib era.
Goldman J
Curr Opin Hematol; 2005 Jan; 12(1):33-9. PubMed ID: 15604889
[TBL] [Abstract][Full Text] [Related]
7. Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment.
Chu S; Xu H; Shah NP; Snyder DS; Forman SJ; Sawyers CL; Bhatia R
Blood; 2005 Mar; 105(5):2093-8. PubMed ID: 15345592
[TBL] [Abstract][Full Text] [Related]
8. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.
Bhatia R; Holtz M; Niu N; Gray R; Snyder DS; Sawyers CL; Arber DA; Slovak ML; Forman SJ
Blood; 2003 Jun; 101(12):4701-7. PubMed ID: 12576334
[TBL] [Abstract][Full Text] [Related]
9. Molecular monitoring of imatinib in chronic myeloid leukemia patients in complete cytogenetic remission: does achievement of a stable major molecular response at any time point identify a privileged group of patients? A multicenter experience in Argentina and Uruguay.
Pavlovsky C; Giere I; Moiraghi B; Pavlovsky MA; Aranguren PN; García J; Fernandez I; Bengió R; Milone J; Labanca V; Uriarte R; Lombardi V; Reinoso FG; Magariños AE; Martinez L; Murro H; Lastiri F; Pavlovsky S
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11(3):280-5. PubMed ID: 21658656
[TBL] [Abstract][Full Text] [Related]
10. How complete is "complete" molecular response in imatinib-treated chronic myeloid leukemia?
Ross DM; Hughes TP
Leuk Lymphoma; 2008 Jul; 49(7):1230-1. PubMed ID: 18604711
[No Abstract] [Full Text] [Related]
11. In search of the original leukemic clone in chronic myeloid leukemia patients in complete molecular remission after stem cell transplantation or imatinib.
Sobrinho-Simões M; Wilczek V; Score J; Cross NC; Apperley JF; Melo JV
Blood; 2010 Aug; 116(8):1329-35. PubMed ID: 20462961
[TBL] [Abstract][Full Text] [Related]
12. CML patient with rare b 2 a 3 (e 13 a 3) variant of BCR-ABL transcript: complete molecular response to imatinib.
Moravcová J; Rulcová J; Polák J; Zemanová Z; Klamová H; Haskovec C
Leuk Res; 2005 Nov; 29(11):1365-6. PubMed ID: 15876454
[No Abstract] [Full Text] [Related]
13. Constant BCR-ABL transcript level >or=0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis.
Poláková KM; Polívková V; Rulcová J; Klamová H; Jurcek T; Dvoráková D; Zácková D; Pospísil Z; Mayer J; Moravcová J
Exp Hematol; 2010 Jan; 38(1):20-6. PubMed ID: 19837125
[TBL] [Abstract][Full Text] [Related]
14. Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABL(IS) or log reduction from the baseline level?
Qin YZ; Jiang Q; Jiang H; Li JL; Li LD; Zhu HH; Lai YY; Lu XJ; Liu YR; Jiang B; Huang XJ
Leuk Res; 2013 Sep; 37(9):1035-40. PubMed ID: 23810191
[TBL] [Abstract][Full Text] [Related]
15. Molecular monitoring in patients with chronic myelogenous leukemia.
Saglio G; Ulisciani S; Fava M; Gottardi E; Cilloni D
Curr Hematol Malig Rep; 2008 Apr; 3(2):65-71. PubMed ID: 20425449
[TBL] [Abstract][Full Text] [Related]
16. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha.
Cortes J; Giles F; O'Brien S; Thomas D; Garcia-Manero G; Rios MB; Faderl S; Verstovsek S; Ferrajoli A; Freireich EJ; Talpaz M; Kantarjian H
Blood; 2003 Jul; 102(1):83-6. PubMed ID: 12637317
[TBL] [Abstract][Full Text] [Related]
17. Chronic myeloid leukemia presenting with extramedullary disease as massive ascites responding to imatinib mesylate.
Aleem A; Siddiqui N
Leuk Lymphoma; 2005 Jul; 46(7):1097-9. PubMed ID: 16019565
[TBL] [Abstract][Full Text] [Related]
18. Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients.
Martinelli G; Iacobucci I; Rosti G; Pane F; Amabile M; Castagnetti F; Cilloni D; Soverini S; Testoni N; Specchia G; Merante S; Zaccaria A; Frassoni F; Saglio G; Baccarani M
Ann Oncol; 2006 Mar; 17(3):495-502. PubMed ID: 16403813
[TBL] [Abstract][Full Text] [Related]
19. Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia.
Wang L; Pearson K; Pillitteri L; Ferguson JE; Clark RE
Br J Haematol; 2002 Sep; 118(3):771-7. PubMed ID: 12181044
[TBL] [Abstract][Full Text] [Related]
20. Different kinetic patterns of BCR-ABL transcript levels in imatinib-treated chronic myeloid leukemia patients after achieving complete cytogenetic response.
Qin YZ; Liu YR; Zhu HH; Li JL; Ruan GR; Zhang Y; Jiang Q; Jiang H; Li LD; Chang Y; Huang XJ; Chen SS
Int J Lab Hematol; 2008 Aug; 30(4):317-23. PubMed ID: 18665830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]